Research programme: stem cell therapies - ReNeuron

Drug Profile

Research programme: stem cell therapies - ReNeuron

Alternative Names: ReN 002

Latest Information Update: 17 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard Medical School; ReNeuron
  • Developer ReNeuron; Schepens Eye Research Institute
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinal disorders
  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 17 Nov 2017 Stem cell therapies are undergoing preclinical development for Retinal disorders in United Kingdom (ReNeuron pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Retinal-disorders in United Kingdom (Parenteral, Implant)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in United Kingdom (Parenteral, Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top